E
Adaptimmune Therapeutics plc
ADAP
$0.3239
$0.01896.20%
E
Sell
3/27/2025Downgrade
Adaptimmune Therapeutics plc (ADAP) was downgraded to E+ from D- on 3/27/2025 due to a decline in the solvency index, total return index and volatility index. Debt to equity increased from 0.68 to 4.64, and the quick ratio declined from 3.54 to 2.6.
Adaptimmune Therapeutics plc (ADAP) was downgraded to E+ from D- on 3/27/2025 due to a decline in the solvency index, total return index and volatility index. Debt to equity increased from 0.68 to 4.64, and the quick ratio declined from 3.54 to 2.6.
D
Sell
2/5/2025Upgraded
Adaptimmune Therapeutics plc (ADAP) was upgraded to D- from E+ on 2/5/2025 due to an increase in the volatility index.
Adaptimmune Therapeutics plc (ADAP) was upgraded to D- from E+ on 2/5/2025 due to an increase in the volatility index.
E
Sell
1/21/2025Downgrade
Adaptimmune Therapeutics plc (ADAP) was downgraded to E+ from D- on 1/21/2025 due to a decline in the volatility index and total return index.
Adaptimmune Therapeutics plc (ADAP) was downgraded to E+ from D- on 1/21/2025 due to a decline in the volatility index and total return index.
D
Sell
1/6/2025Upgraded
Adaptimmune Therapeutics plc (ADAP) was upgraded to D- from E+ on 1/6/2025 due to an increase in the volatility index and solvency index. The quick ratio increased from 2.91 to 3.54.
Adaptimmune Therapeutics plc (ADAP) was upgraded to D- from E+ on 1/6/2025 due to an increase in the volatility index and solvency index. The quick ratio increased from 2.91 to 3.54.
E
Sell
11/12/2024Downgrade
Adaptimmune Therapeutics plc (ADAP) was downgraded to E+ from D- on 11/12/2024 due to a decline in the volatility index.
Adaptimmune Therapeutics plc (ADAP) was downgraded to E+ from D- on 11/12/2024 due to a decline in the volatility index.
D
Sell
2/7/2024Upgraded
Adaptimmune Therapeutics plc (ADAP) was upgraded to D- from E+ on 2/7/2024 due to an increase in the solvency index and volatility index.
Adaptimmune Therapeutics plc (ADAP) was upgraded to D- from E+ on 2/7/2024 due to an increase in the solvency index and volatility index.
E
Sell
5/25/2023Downgrade
Adaptimmune Therapeutics plc (ADAP) was downgraded to E+ from D- on 5/25/2023 due to a decline in the volatility index.
Adaptimmune Therapeutics plc (ADAP) was downgraded to E+ from D- on 5/25/2023 due to a decline in the volatility index.
D
Sell
5/5/2023Upgraded
Adaptimmune Therapeutics plc (ADAP) was upgraded to D- from E+ on 5/5/2023 due to an increase in the volatility index and growth index.
Adaptimmune Therapeutics plc (ADAP) was upgraded to D- from E+ on 5/5/2023 due to an increase in the volatility index and growth index.
E
Sell
4/20/2023Downgrade
Adaptimmune Therapeutics plc (ADAP) was downgraded to E+ from D- on 4/20/2023 due to a decline in the volatility index and total return index.
Adaptimmune Therapeutics plc (ADAP) was downgraded to E+ from D- on 4/20/2023 due to a decline in the volatility index and total return index.
D
Sell
3/30/2023Upgraded
Adaptimmune Therapeutics plc (ADAP) was upgraded to D- from E+ on 3/30/2023 due to an increase in the volatility index.
Adaptimmune Therapeutics plc (ADAP) was upgraded to D- from E+ on 3/30/2023 due to an increase in the volatility index.
E
Sell
3/15/2023Downgrade
Adaptimmune Therapeutics plc (ADAP) was downgraded to E+ from D- on 3/15/2023 due to a decline in the volatility index and total return index.
Adaptimmune Therapeutics plc (ADAP) was downgraded to E+ from D- on 3/15/2023 due to a decline in the volatility index and total return index.
D
Sell
3/14/2023Downgrade
Adaptimmune Therapeutics plc (ADAP) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index, solvency index and volatility index. Debt to equity increased from 0.02 to 0.03, and the quick ratio declined from 3.83 to 3.76.
Adaptimmune Therapeutics plc (ADAP) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index, solvency index and volatility index. Debt to equity increased from 0.02 to 0.03, and the quick ratio declined from 3.83 to 3.76.
D
Sell
2/23/2023Upgraded
Adaptimmune Therapeutics plc (ADAP) was upgraded to D from D- on 2/23/2023 due to an increase in the volatility index.
Adaptimmune Therapeutics plc (ADAP) was upgraded to D from D- on 2/23/2023 due to an increase in the volatility index.
D
Sell
2/8/2023Downgrade
Adaptimmune Therapeutics plc (ADAP) was downgraded to D- from D on 2/8/2023 due to a decline in the solvency index. The quick ratio declined from 4.18 to 3.83.
Adaptimmune Therapeutics plc (ADAP) was downgraded to D- from D on 2/8/2023 due to a decline in the solvency index. The quick ratio declined from 4.18 to 3.83.
D
Sell
5/5/2022Upgraded
Adaptimmune Therapeutics plc (ADAP) was upgraded to D from D- on 05/05/2022.
Adaptimmune Therapeutics plc (ADAP) was upgraded to D from D- on 05/05/2022.
D
Sell
4/20/2022Downgrade
Adaptimmune Therapeutics plc (ADAP) was downgraded to D- from D on 4/20/2022 due to a substantial decline in the total return index, volatility index and solvency index. The quick ratio declined from 6.93 to 6.45.
Adaptimmune Therapeutics plc (ADAP) was downgraded to D- from D on 4/20/2022 due to a substantial decline in the total return index, volatility index and solvency index. The quick ratio declined from 6.93 to 6.45.
D
Sell
11/23/2021Upgraded
Adaptimmune Therapeutics plc (ADAP) was upgraded to D from D- on 11/23/2021 due to an increase in the total return index and volatility index.
Adaptimmune Therapeutics plc (ADAP) was upgraded to D from D- on 11/23/2021 due to an increase in the total return index and volatility index.
D
Sell
11/8/2021Downgrade
Adaptimmune Therapeutics plc (ADAP) was downgraded to D- from D on 11/8/2021 due to a decline in the growth index and valuation index. Total revenue declined 61.13% from $3.1M to $1.2M, operating cash flow declined 43.68% from -$31.46M to -$45.2M, and earnings per share declined from -$1.5054 to -$1.8.
Adaptimmune Therapeutics plc (ADAP) was downgraded to D- from D on 11/8/2021 due to a decline in the growth index and valuation index. Total revenue declined 61.13% from $3.1M to $1.2M, operating cash flow declined 43.68% from -$31.46M to -$45.2M, and earnings per share declined from -$1.5054 to -$1.8.
D
Sell
5/1/2020Upgraded
Adaptimmune Therapeutics plc (ADAP) was upgraded to D from D- on 5/1/2020 due to a noticeable increase in the growth index, volatility index and total return index. Total revenue increased 207.17% from $237 to $728, operating cash flow increased 57.69% from -$29.61M to -$12.53M, and EBIT increased 24.34% from -$40.12M to -$30.36M.
Adaptimmune Therapeutics plc (ADAP) was upgraded to D from D- on 5/1/2020 due to a noticeable increase in the growth index, volatility index and total return index. Total revenue increased 207.17% from $237 to $728, operating cash flow increased 57.69% from -$29.61M to -$12.53M, and EBIT increased 24.34% from -$40.12M to -$30.36M.
D
Sell
5/16/2019Downgrade
Adaptimmune Therapeutics plc (ADAP) was downgraded to D- from D on 5/16/2019 due to a significant decline in the total return index, growth index and volatility index. Operating cash flow declined 14.26% from -$31.69M to -$36.2M, and EBIT declined 5.25% from -$32.11M to -$33.79M.
Adaptimmune Therapeutics plc (ADAP) was downgraded to D- from D on 5/16/2019 due to a significant decline in the total return index, growth index and volatility index. Operating cash flow declined 14.26% from -$31.69M to -$36.2M, and EBIT declined 5.25% from -$32.11M to -$33.79M.
D
Sell
5/15/2018Downgrade
Adaptimmune Therapeutics plc (ADAP) was downgraded to D from D+ on 5/15/2018 due to a decline in the efficiency index and valuation index. Total capital declined 5.77% from $202.98M to $191.26M.
Adaptimmune Therapeutics plc (ADAP) was downgraded to D from D+ on 5/15/2018 due to a decline in the efficiency index and valuation index. Total capital declined 5.77% from $202.98M to $191.26M.
D
Sell
4/3/2018Upgraded
Adaptimmune Therapeutics plc (ADAP) was upgraded to D+ from D on 4/3/2018 due to an increase in the total return index.
Adaptimmune Therapeutics plc (ADAP) was upgraded to D+ from D on 4/3/2018 due to an increase in the total return index.
D
Sell
3/19/2018Downgrade
Adaptimmune Therapeutics plc (ADAP) was downgraded to D from D+ on 3/19/2018 due to a substantial decline in the growth index, solvency index and efficiency index. Net income declined 3,005.13% from -$878 to -$27.26M, earnings per share declined from -$0.0564 to -$1.7478, and EBIT declined 498.79% from -$4.96M to -$29.7M.
Adaptimmune Therapeutics plc (ADAP) was downgraded to D from D+ on 3/19/2018 due to a substantial decline in the growth index, solvency index and efficiency index. Net income declined 3,005.13% from -$878 to -$27.26M, earnings per share declined from -$0.0564 to -$1.7478, and EBIT declined 498.79% from -$4.96M to -$29.7M.
D
Sell
2/9/2018Downgrade
Adaptimmune Therapeutics plc (ADAP) was downgraded to D+ from C- on 2/9/2018 due to a decline in the volatility index and total return index.
Adaptimmune Therapeutics plc (ADAP) was downgraded to D+ from C- on 2/9/2018 due to a decline in the volatility index and total return index.
C
Hold
1/25/2018Upgraded
Adaptimmune Therapeutics plc (ADAP) was upgraded to C- from D+ on 1/25/2018 due to a noticeable increase in the total return index and volatility index.
Adaptimmune Therapeutics plc (ADAP) was upgraded to C- from D+ on 1/25/2018 due to a noticeable increase in the total return index and volatility index.
D
Sell
11/3/2017Upgraded
Adaptimmune Therapeutics plc (ADAP) was upgraded to D+ from D on 11/3/2017 due to a significant increase in the growth index, solvency index and total return index. Total revenue increased 672.08% from $3.52M to $27.19M, operating cash flow increased 174.9% from -$18.01M to $13.49M, and earnings per share increased from -$1.3068 to -$0.0564.
Adaptimmune Therapeutics plc (ADAP) was upgraded to D+ from D on 11/3/2017 due to a significant increase in the growth index, solvency index and total return index. Total revenue increased 672.08% from $3.52M to $27.19M, operating cash flow increased 174.9% from -$18.01M to $13.49M, and earnings per share increased from -$1.3068 to -$0.0564.
D
Sell
7/31/2017Upgraded
Adaptimmune Therapeutics plc (ADAP) was upgraded to D from D- on 7/31/2017 due to an increase in the efficiency index, total return index and valuation index. Total capital increased 25.39% from $166.14M to $208.33M.
Adaptimmune Therapeutics plc (ADAP) was upgraded to D from D- on 7/31/2017 due to an increase in the efficiency index, total return index and valuation index. Total capital increased 25.39% from $166.14M to $208.33M.
D
Sell
8/12/2016Downgrade
Adaptimmune Therapeutics plc (ADAP) was downgraded to D- from D on 8/12/2016 due to a noticeable decline in the growth index, efficiency index and solvency index. Total revenue declined 88.76% from $2.92M to $328, earnings per share declined from -$0.22 to -$0.3121, and net income declined 41.85% from -$15.58M to -$22.1M.
Adaptimmune Therapeutics plc (ADAP) was downgraded to D- from D on 8/12/2016 due to a noticeable decline in the growth index, efficiency index and solvency index. Total revenue declined 88.76% from $2.92M to $328, earnings per share declined from -$0.22 to -$0.3121, and net income declined 41.85% from -$15.58M to -$22.1M.
D
Sell
6/7/2016Upgraded
Adaptimmune Therapeutics plc (ADAP) was upgraded to D from D- on 6/7/2016 due to an increase in the growth index, efficiency index and valuation index.
Adaptimmune Therapeutics plc (ADAP) was upgraded to D from D- on 6/7/2016 due to an increase in the growth index, efficiency index and valuation index.
D
Sell
2/1/2016Upgraded
Adaptimmune Therapeutics plc (ADAP) was upgraded to D- from E+ on 2/1/2016 due to an increase in the growth index. EBIT increased 44.29% from -$7.29M to -$10.53M, and total revenue increased 20.05% from $3.36M to $4.03M.
Adaptimmune Therapeutics plc (ADAP) was upgraded to D- from E+ on 2/1/2016 due to an increase in the growth index. EBIT increased 44.29% from -$7.29M to -$10.53M, and total revenue increased 20.05% from $3.36M to $4.03M.
E
Sell
11/2/2015Upgraded
Adaptimmune Therapeutics plc (ADAP) was upgraded to E+ from E on 11/2/2015 due to a major increase in the solvency index and growth index. Operating cash flow increased 1.32% from -$8.39M to -$8.5M, EBIT increased 1.32% from -$7.2M to -$7.29M, and total revenue increased 1.31% from $3.31M to $3.36M.
Adaptimmune Therapeutics plc (ADAP) was upgraded to E+ from E on 11/2/2015 due to a major increase in the solvency index and growth index. Operating cash flow increased 1.32% from -$8.39M to -$8.5M, EBIT increased 1.32% from -$7.2M to -$7.29M, and total revenue increased 1.31% from $3.31M to $3.36M.
E
Sell
8/21/2015Downgrade
Adaptimmune Therapeutics plc (ADAP) was downgraded to E from D+ on 8/21/2015 due to a decline in the total return index.
Adaptimmune Therapeutics plc (ADAP) was downgraded to E from D+ on 8/21/2015 due to a decline in the total return index.
D
Sell
8/13/2015Upgraded
Adaptimmune Therapeutics plc (ADAP) was upgraded to D+ from E on 08/13/2015.
Adaptimmune Therapeutics plc (ADAP) was upgraded to D+ from E on 08/13/2015.
E
Sell
8/7/2015Downgrade
Adaptimmune Therapeutics plc (ADAP) was downgraded to E from D+ on 08/07/2015.
Adaptimmune Therapeutics plc (ADAP) was downgraded to E from D+ on 08/07/2015.
D
Sell
7/31/2015None
Adaptimmune Therapeutics plc (ADAP) was downgraded to D+ from U on 07/31/2015.
Adaptimmune Therapeutics plc (ADAP) was downgraded to D+ from U on 07/31/2015.
NASDAQ
04/03/2025 4:00PM Eastern
Quotes delayed
